ELIXIRON IMMUNOTHERAPEUTICS

Elixiron Immunotherapeutics is driven by an international team with a shared vision to produce next-generation immunotherapies. This vision drives our mission to target rare and inflammatory disorders as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain... phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.

#People #Financial #Website #More

ELIXIRON IMMUNOTHERAPEUTICS

Social Links:

Industry:

Biotechnology

Founded:

2017-01-01

Address:

Taipei, T'ai-pei, Taiwan

Country:

Taiwan

Website Url:

http://www.elixiron.com

Total Employee:

11+

Status:

Active

Total Funding:

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Microsoft Exchange Online Office 365 Mail ASP.NET IIS ASP.NET 4.0 GoDaddy SSL

Current Employees Featured

hung-kai-chen_image

Hung-Kai Chen
Hung-Kai Chen CEO @ Elixiron Immunotherapeutics
CEO

Founder

hung-kai-chen_image

Hung-Kai Chen

Investors List

alzheimer-s-association_image

Official Site Inspections

http://www.elixiron.com Semrush global rank: 7 M Semrush visits lastest month: 646

Host Informations
Whois Informations

Loading ...